Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2015

View Archived Issues

Almirall describes novel CRAC channel inhibitors

Discovery, structure of AG-221 presented by Agios Pharmaceuticals

Stemcell Technologies licenses research assets from iPS Academia Japan

RedHill Biopharma hires Recipharm to manufacture phase III candidate

Amgen gives details on discovery of AMG-337

MSI Methylation announces last patient treated in phase II trial of ademetionine in MDD

Oncoceutics announces start of expansion phase in first-in-human ONC-201 trial

GSK poised to begin first-in-human trial of GSK-3174998

Janssen Pharmaceutical presents FFAR4 agonists

Edoxaban endorsed by NICE

Advaxis enters into licensing agreement with Knight Therapeutics for Canada

Bayer Schering Pharma discloses BRD4 inhibitors

RespiVert and Topivert Pharma patent anti-inflammatory kinase inhibitors

Tissue Therapies partners with the Queensland University of Technology on research

Incyte divulges KDM1A inhibitors

Principia Biopharma presents FGFR inhibitors

Alvogen to acquire product portfolio from Pfizer for the U.S.

Global trial of palbociclib launched for patients with hormone receptor-positive early breast cancer

Audentes Therapeutics' AT-001 receives orphan drug designation

Syndax and Genentech to conduct phase Ib/II trial combining entinostat and atezolizumab

Novel nanoparticle-based Epstein-Barr virus vaccine elicits potent antibody responses

Valneva updates on 2015 EB66 licensing agreements

Novo Nordisk begins phase IIIa development of oral semaglutide

Daratumumab gains third FDA orphan drug designation

Strategies focused on the HA stem advance universal influenza vaccine development

Allied-Bristol licenses antibody-recruiting molecule technology from Yale

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...